Read More Pharma Industry News What the CHMP’s positive view on lomitapide reveals about the evolving HoFH treatment landscape in children See how Chiesi Group’s paediatric lomitapide expansion could reshape HoFH treatment access, payer dynamics, and rare disease growth across Europe. bySoujanya RaviApril 2, 2026